Introduction: Interstitial lung diseases (ILDs) are associated with a high economic burden, yet prospective data of the German healthcare system are sparse. Objective: We assessed average ILD-related
Changes in level and slope in patients’ costs on medications (ME), antibiotics (AN), and on the very-restricted (VR) antibiotics were analyzed for both inpatients and outpatients in the 65 general hos